Document:

Filed by Bowne Pure Compliance

Exhibit 10.1

Memory Pharmaceuticals Corp.

100 Philips Parkway

Montvale, New Jersey 07645

Phone: (201) 802-7100

Fax: (201) 802-7190

www.memorypharma.com

September 29, 2008

Mr. James R. Sulat

Dear Jim:

This letter reflects the change in your position with Memory Pharmaceuticals Corp. (the
“Company”), effective February 7, 2008 (the “Effective Date”) and shall be effective as of the
Effective Date. This agreement (other than Section 5 (“Indemnification”) and 6 (“Confidentiality”)
shall expire on December 31, 2009, unless extended by mutual agreement between you and the Company
or terminated earlier, pursuant to section 2, below, provided that the Company shall be obligated
to make any payment required under Section 3(c) after this agreement expires if such obligation
arises on account of a separation from service that occurs before the agreement expires.

1. Position. Beginning on the Effective Date, your position will be Chief Financial
Officer, based out of the Company’s offices currently located in Montvale, New Jersey, and you will
report to the Company’s Chief Executive Officer. You are expected to perform your duties on a
part-time basis, spending approximately 50% of the time in your position as would a full-time
employee.

You agree not to engage in any activities outside of the scope of your employment that would
detract from, or interfere with, the fulfillment of your responsibilities or duties under this
letter agreement. You agree that you will not serve as a director or the equivalent position of
any company or entity, and will not render services of a business, professional or commercial
nature to any other person or firm, except for not-for-profit entities, without the prior written
consent of the Board. You further agree that, if you cease to be an executive officer of the
Company, you will resign from the Board, unless the Board requests otherwise.

2. Nature of Relationship. No provision of this letter agreement shall be construed
to create an express or implied employment contract for a specific period of time. Either you or
the Company may terminate the employment relationship at any time and for any reason, by giving at
least thirty (30) days’ prior written notice to the other party. The Company in its sole
discretion may elect to terminate your employment immediately or during such thirty (30) day notice
period, but in this event you will continue to be paid through the end of the thirty (30) day
notice period.

 

 

 

MEMORY PHARMACEUTICALS CORP.

Mr. James R. Sulat

3. Compensation.

(a) Beginning on the Effective date, your semi-monthly base salary shall be 50% of your
semi-monthly base salary in effect immediately before the Effective Date.

(b) You will be eligible to receive an annual bonus dependent on the performance of the
Company and your individual performance, subject to the discretion of the Board. Your
current target bonus will be equal to thirty-five percent (35%) of your annualized base
salary (determined as if you were a full-time employee), assuming the achievement of such
Company and individual performance objectives. The actual amount paid, if any, shall be
determined by the Board in its sole discretion, or a committee thereof. The Company will
pay any annual bonus payment during the calendar year following the year in which the
Company and individual performance objectives are satisfied. Your target bonus for future
years will be determined by the Board of Directors, in its sole discretion, or a committee
thereof.

(c) Upon your “Separation From Service” (as defined in paragraph 3(g)) for any reason,
the Company will pay you, within two (2) weeks of such Separation From Service, your current
base salary earned through the Separation From Service date, plus accrued vacation, if any,
and other benefits or payments, if any, to which you are entitled. In addition, you may be
entitled to severance benefits as described below, except that, notwithstanding the
provisions below, no additional benefits will be provided if you are terminated for Cause:

(i) Separation From Service on or before December 31, 2008, for any reason by you
other than for Good Reason. In the event of your Separation From Service on or
before December 31, 2008, for any reason by you other than for Good Reason (as
defined below)—

(A) the Company will pay you, in the seventh month following your Separation
From Service, a severance amount equal to the sum of (I) twelve (12) months
of your base salary in effect at the time of Separation From Service
(determined, however, as if you were a full-time employee), less applicable
deductions, and (II) the average of your annual bonuses for the previous
three calendar years;

(B) you will be entitled to accelerated vesting of twenty-five percent (25%)
of your unvested stock options as of the date of your Separation From
Service; and

(C) for a period of twelve (12) months after your Separation From Service,
the Company shall provide and pay for the Company’s portion of your group
medical and dental insurance, which shall count towards the applicable
benefit continuation period required by applicable law.

(ii) Separation From Service on or before December 31, 2008, by the Company without
Cause or by you for Good Reason. In the event of your Separation From Service on or
before December 31, 2008, by the Company without Cause or by you for Good Reason—

(A) the Company shall continue to pay you your semi-monthly base salary
through December 31, 2008, and you shall continue to be eligible for and you
shall continue vesting in your stock options through December 31, 2008, as
if you had continued to work for the Company through that date (except with
respect to any incentive stock options, as described below);

(B) the Company will pay you, in the seventh month following your Separation
From Service, a severance amount equal to the sum of (I) twelve (12) months
of your base salary in effect at the time of Separation From Service
(determined,

 

2

 

MEMORY PHARMACEUTICALS CORP.

Mr. James R. Sulat

however, as if you were a full-time employee), less applicable deductions,
and (II) the average of your annual bonuses for the previous three calendar
years;

(C) you will be entitled to accelerated vesting of twenty-five percent (25%)
of your unvested stock options as of December 31, 2008; and

(D) for the remainder of the 2008 calendar year and for the entire 2009
calendar year, the Company shall provide and pay for the Company’s portion
of your group medical and dental insurance, which shall count towards the
applicable benefit continuation period required by applicable law.

(iii) Separation From Service after December 31, 2008, for any reason. In the event
of your Separation From Service after December 31, 2008, for any reason (other than
by the Company for Cause) —

(A) the Company will pay you, in the seventh month following your Separation
From Service, a severance amount equal to the sum of (I) twelve (12) months
of your base salary in effect at the time of Separation From Service
(determined, however, as if you were a full-time employee), less applicable
deductions, and (II) the average of your annual bonuses for the previous
three calendar years;

(B) you will be entitled to accelerated vesting of twenty-five percent (25%)
of your unvested stock options as of the date of your Separation From
Service; and

(C) for a period of twelve (12) months after your Separation From Service,
the Company shall provide and pay for the Company’s portion of your group
medical and dental insurance, which shall count towards the applicable
benefit continuation period required by applicable law.

If group medical and dental insurance continues after your Separation From Service
pursuant to this paragraph 3(c), you will continue to be responsible for your portion of the
cost of your group health insurance for the period specified under this paragraph 3(c).
During such period, the Company will reconcile such payments with you quarterly, and any
additional payments owed to you by the Company, and any payments owed to the Company by you,
will be paid respectively within two (2) weeks following such reconciliation period.
Thereafter, should you choose to continue such benefits through the remainder of the
continuation period, you will be responsible for the full cost.

With respect to your vested incentive stock options, such options must be exercised by
you within ninety (90) days after the Separation From Service and (ii) with respect to your
vested non-qualified stock options, such options must be exercised by you on or before the
date that is the later to occur of (i) ninety (90) days after the date of your Separation
From Service or (ii) January 15th of the calendar year immediately succeeding the
date of your Separation From Service. The Company will not be obligated to continue any
such payments to you or accelerate vesting of your stock options under this paragraph 3(c)
in the event you materially breach the terms of this letter agreement or the Confidentiality
Agreement (as defined below). Notwithstanding any Separation From Service for any reason
(with or without Cause or for Good Reason), you will continue to be bound by the provisions
of the Confidentiality Agreement.

All payments and benefits provided pursuant to this paragraph 3(c) shall be conditioned
upon your execution and non-revocation of a general release substantially in the form
attached hereto as Exhibit A at the time of Separation From Service. Your refusal
to execute a general release shall constitute a waiver by you of any and all benefits
referenced in this paragraph 3(c). The Company will not be obligated to continue any such
payments to you under this paragraph 3(c) in the event you materially breach the terms of
this letter agreement or the Confidentiality Agreement.

 

3

 

MEMORY PHARMACEUTICALS CORP.

Mr. James R. Sulat

(d) For the purposes of this paragraph 3, “Cause” shall include (i) your conviction of
a felony, either in connection with the performance of your obligations to the Company or
otherwise, which adversely affects your ability to perform such obligations or materially
adversely affects the business activities, reputation, goodwill or image of the Company,
(ii) your willful disloyalty, deliberate dishonesty, breach of fiduciary duty, (iii) your
breach of the terms of this letter agreement, or your failure or refusal to carry out any
material tasks or responsibilities assigned to you by the Company in accordance with the
terms hereof, which breach or failure continues for a period of more than thirty (30) days
after your receipt of written notice thereof from the Company, (iv) the commission by you of
any act of fraud, embezzlement or deliberate disregard of a significant rule or policy of
the Company known to you or contained in a policy and procedure manual provided to you which
results in material loss, damage or injury to the Company, or (v) the material breach by
you of any of the provisions of the Confidentiality Agreement.

(e) For the purpose of this paragraph 3, Separation From Service for “Good Reason”
shall mean a Separation From Service that occurs following submission of your written
resignation in accordance with paragraph 2. For purposes of a Separation From Service for
Good Reason, the Separation From Service must occur within two (2) years of the event
triggering such written resignation. Your written resignation for Good Reason must be
received:

(i) within ninety (90) calendar days after a material diminution in your
responsibilities (provided that such diminution is not in connection with a Separation From
Service for Cause or as specifically contemplated by this agreement),

(ii) within ninety (90) calendar days after you no longer report to the Chief Executive
Officer or cease to be a member of the Board (other than as a result of any act or
circumstance relating to your inability, failure or refusal to serve as a member of the
Board or as a result of your ceasing to be an executive officer of the Company),

(iii) within ninety (90) calendar days of your principal work location changing to be
more than fifty (50) miles from the Company’s principal offices, or

(iv) within ninety (90) calendar days after any material reduction by the Company of
the amount of your base salary, unless such reduction is pursuant to a plan and as a
consequence the base salaries of the Company’s executives are reduced generally.

Provided, however, that with respect to any of the foregoing events, you shall be
required to provide the Company written notice of the existence of the condition within
ninety (90) calendar days after the initial existence of the condition, and the Company
shall have the opportunity to cure such event if such event is capable of being cured within
thirty (30) days after it receives such notice.

(f) If within three (3) months prior to, or within eighteen (18) months after, the
occurrence of a Change of Control (as defined below), you incur a Separation From Service by
the Company without Cause or by you for Good Reason, your unvested stock options will become
fully vested on the date of your Separation From Service. For the purposes of this letter
agreement, “Change of Control” shall be deemed to have occurred if the Company is
consolidated with or acquired by another entity in a merger, sale of all or substantially
all of the Company’s assets or shares of stock or otherwise (excluding (A) transactions
solely for the purpose of reincorporating the Company in a different jurisdiction or
recapitalizing or reclassifying the Company’s stock, or (B) any merger or consolidation in
which the shareholders of the Company immediately prior to such merger or consolidation
continue to own at least a majority of

 

4

 

MEMORY PHARMACEUTICALS CORP.

Mr. James R. Sulat

the outstanding voting securities of the Company or the surviving entity after such
merger of consolidation).

(g) For purposes of this letter agreement, “Separation From Service” shall mean
Separation From Service with the Company within the meaning of section 409A of the Code. In
accordance with section 409A, a Separation From Service will generally occur: (i) on the day
that no further services will be performed by you or that the level of services that you
perform for the Company permanently decreases to no more than twenty percent (20%) of the
average level of bona fide services you performed over the immediately preceding thirty-six
(36) month period (or such shorter period if you have not been employed for thirty-six (36)
months); (ii) on the first day immediately following six (6) months of a bona fide leave of
absence period that is not due to a medically determinable physical or mental impairment
that can be expected to result in death or to last for a continuous period of not less than
six months, or (iii) on the first day immediately following twenty-nine (29) months of a
bona fide leave of absence period that is due to a medically determinable physical or mental
impairment that can be expected to result in death or to last for a continuous period of not
less than six (6) months. However, a Separation From Service does not occur during a leave
if you have the right to return under an applicable statute or by contract.

4. Benefits. You will be entitled as an employee of the Company to receive such
benefits as are generally provided its employees and executives and for which you are eligible in
accordance with Company policy as in effect from time to time. The Company retains the right to
change, add or cease any particular benefit relating to its employees and executives generally. At
this time, the Company is offering a benefit program, consisting of medical, dental, life and
short/long term disability insurance, as well as a 401(k) retirement plan and flexible spending
plan. You will be eligible for eleven (11) paid holidays in addition to Paid Time Off, which
accrues in accordance with Company policy.

5. Indemnification. To the extent permissible under applicable law, the Company will
indemnify you for expenses incurred or damages paid or payable by you with respect to a claim
against you, including amounts paid or payable by you upon the settlement of a claim against you,
where such claim is based on actions or failures by you in your capacity as an executive officer
and/or as a member of the Company’s Board.

6. Confidentiality. The Company considers the protection of its confidential
information and proprietary materials to be very important. Therefore, as a condition of your
employment, you remain subject to the Confidentiality and Noncompetition Agreement in the form of
Exhibit B attached hereto (the “Confidentiality Agreement”).

7. General.

(a) This letter agreement, together with the Confidentiality Agreement and any
outstanding Stock Option Agreement, will constitute our entire agreement as to your
employment by the Company and will supersede any prior agreements or understandings, whether
in writing or oral.

(b) This letter agreement shall be governed by the law of the State of New Jersey. In
the event of any legal proceedings relating to this letter agreement and/or the subject
matter thereof, the parties consent to the exclusive jurisdiction of the courts located in
the State of New Jersey. THE PARTIES HEREBY EXPRESSLY WAIVE THEIR RIGHT TO HAVE A JURY
TRIAL.

 

5

 

MEMORY PHARMACEUTICALS CORP.

Mr. James R. Sulat

You may accept this restated employment agreement by signing the enclosed additional copy of
this letter agreement, which execution will evidence your agreement with the terms set forth
herein, and returning this letter agreement to the Company.

We look forward to your continued contributions to Memory’s growth and your prompt response to
this letter.

Sincerely,

MEMORY PHARMACEUTICALS CORP.

	 	 	 	 	 
	By:

	 	/s/ Vaughn M. Kailian
	 	 
	 

	 	 	 	 
	Name:

	 	Vaughn M. Kailian	 	 
	Title:

	 	President and Chief Executive Officer	 	 

ACCEPTED AND AGREED:

	 	 	 
	/s/ James R. Sulat

	 	 
	 	 	 
	James R. Sulat
	 	 

Date: September 30, 2008

 

6

 

EXHIBIT A

FORM OF GENERAL RELEASE OF CLAIMS

GENERAL RELEASE OF CLAIMS

For and in consideration of the payments and other benefits described in the letter agreement
dated as of                     , 2008 (the “Letter Agreement”) by and between Memory Pharmaceuticals Corp.
(the “Company”), and James R. Sulat (“Employee”) and for other good and valuable consideration,
Employee hereby releases the Company and its respective divisions, operating companies, affiliates,
subsidiaries, parents, branches, predecessors, successors, assigns, officers, directors, trustees,
employees, agents, shareholders, administrators, representatives, attorneys, insurers and
fiduciaries, past, present and future (the “Released Parties”), from any and all claims of any kind
arising out of or related to Employee’s employment with the Company, Employee’s separation from
employment with the Company or derivative of Employee’s employment, which Employee now has or may
have against the Released Parties, whether known or unknown to Employee, by reason of facts which
have occurred on or prior to the date that Employee has signed this General Release of Claims.
Such released claims include, without limitation, any alleged violation of the Age Discrimination
in Employment Act, as amended, the Older Worker Benefits Protection Act; Title VII of the Civil
Rights of 1964, as amended; Sections 1981 through 1988 of Title 42 of the United States Code; the
Civil Rights Act of 1991; the Equal Pay Act; the Americans with Disabilities Act; the
Rehabilitation Act; the Family and Medical Leave Act; the Fair Labor Standards Act; the Employee
Retirement Income Security Act of 1974, as amended; the Worker Adjustment and Retraining
Notification Act; the National Labor Relations Act; the Fair Credit Reporting Act; the Occupational
Safety and Health Act; the Uniformed Services Employment and Reemployment Act; the Employee
Polygraph Protection Act; the Immigration Reform Control Act; the retaliation provisions of the
Sarbanes-Oxley Act of 2002; the Federal False Claims Act; the New Jersey Law Against
Discrimination; the New Jersey Domestic Partnership Act; the New Jersey Conscientious Employee
Protection Act; the New Jersey Family Leave Act; the New Jersey Wage and Hour Law; the New Jersey
Equal Pay Law; the New Jersey Occupational Safety and Health Law; the New Jersey Smokers’ Rights
Law; the New Jersey Genetic Privacy Act; the New Jersey Fair Credit Reporting Act; the retaliation
provisions of the New Jersey Workers’ Compensation Law (and including any and all amendments to the
above) and/or any other alleged violation of any federal, state or local law, regulation or
ordinance, and/or contract or implied contract or tort law or public policy or whistleblower claim,
having any bearing whatsoever on Employee’s employment by and the termination of Employee’s
employment with the Company, including, but not limited to, any claim for wrongful discharge, back
pay, vacation pay, sick pay, wage, commission or bonus payment, money or equitable relief or
damages of any kind, attorneys’ fees, costs, and/or future wage loss.

It is understood that this General Release of Claims is not intended to and does not affect or
release any future rights or any claims arising after the date hereof.

Employee understands that the consideration provided to him under the terms of the Letter
Agreement or otherwise does not constitute an admission by the Company that it has violated any law
or legal obligation.

Employee agrees, to the fullest extent permitted by law, that he will not commence, maintain,
prosecute or participate in any action or proceeding of any kind against the Company based on any
of the claims waived herein occurring up to and including the date of his signature. Employee
represents and warrants that he has not done so as of the effective date of this General Release of
Claims. Notwithstanding the foregoing agreement, representation and warranty, if Employee violates
any of the provisions of this paragraph, Employee agrees to indemnify and hold harmless the Company
from and against any and all costs, attorneys’ fees and other expenses authorized by law which
result from, or are incident to, such violation. This paragraph is not intended to preclude
Employee from (1) enforcing the terms of the Letter Agreement; (2) challenging the knowing and
voluntary nature of this General Release of Claims; or (3) filing a charge or participating in any
investigation or proceeding conducted by the Equal Employment Opportunity Commission.

 

Exhibit A — Page 1

 

Employee further agrees to waive his right to any monetary or equitable recovery should any
federal, state or local administrative agency pursue any claims on his behalf arising out of or
related to his employment with and/or separation from employment with the Company and promises not
to seek or accept any award, settlement or other monetary or equitable relief from any source or
proceeding brought by any person or governmental entity or agency on his behalf or on behalf of any
class of which he is a member with respect to any of the claims he has waived.

Employee acknowledges and agrees that Employee has read this General Release of Claims
carefully, and acknowledges that he has been given at least twenty one (21) days from the date of
receipt of this General Release of Claims to consider all of its terms and has been advised to
consult with any attorney and any other advisors of the Employee’s choice prior to executing this
General Release of Claims. Employee fully understands that, by signing below, Employee is
voluntarily giving up any right which Employee may have to sue or bring any other claims against
the Released Parties, including any rights and claims under the Age Discrimination in Employment
Act. The terms of this General Release of Claims shall not become effective or enforceable until
eight (8) days following the date of its execution by Employee, during which time Employee may
revoke the Letter Agreement. Employee may revoke the Letter Agreement by notifying the Company in
writing (to the attention of the Executive Chairman with a copy to Vice President of Legal
Affairs). For Employee’s revocation to be effective, written notice must be received by no later
than the close of business on the eighth (8th) day after Employee signs this General
Release of Claims. The terms of this offer to provide the payments and other benefits described in
paragraph 3(c) of the Letter Agreement, will expire if not accepted during the 21 day review
period.

Employee agrees to keep confidential all information contained in this General Release of
Claims and relating to this General Release of Claims, except (1) to the extent the Company
consents in writing to such disclosure; (2) if Employee is required by process of law to make such
disclosure and Employee promptly notifies the Company of his receipt of such process; or (3)
because Employee must disclose certain terms on a confidential basis to his financial consultant,
attorney or spouse.

This General Release of Claims shall be construed and enforced in accordance with, and
governed by, the laws of the State of New Jersey, without regard to principles of conflict of laws.
If any clause of this General Release of Claims should ever be determined to be unenforceable, it
is agreed that this will not affect the enforceability of any other clause or the remainder of this
General Release of Claims.

This General Release of Claims is final and binding and may not be changed or modified except
as set forth herein or in a writing signed by both parties. The parties have executed this General
Release of Claims with full knowledge of any and all rights they may have, and they hereby assume
the risk of any mistake in fact in connection with the true facts involved, or with regard to any
facts which are now unknown to them.

By signing this General Release of Claims, Employee acknowledges that: (1) he has read this
General Release of Claims completely; (2) he has had an opportunity to consider the terms of this
General Release of Claims; (3) he has had the opportunity to consult with an attorney of his
choosing prior to executing this General Release of Claims to explain this General Release of
Claims and its consequences; (4) he knows that he is giving up important legal rights by signing
this General Release of Claims; (5) he has not relied on any representation or statement not set
forth in this General Release of Claims; (6) he understands and means everything that he has said
in this General Release of Claims, and he agrees to all its terms; and (7) he has signed this
General Release of Claims voluntarily and entirely of his own free will.

	 	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	 	 	 
	Date

	 	James R. Sulat
	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	 	 	 
	Date

	 	Memory Pharmaceuticals Corp.	 	 

 

Exhibit A — Page 2

 

EXHIBIT B

FORM OF CONFIDENTIALITY AGREEMENT

Memory Pharmaceuticals Corp.

100 Philips Parkway

Montvale, New Jersey 07645

Phone: (201) 802-7100

Fax: (201) 802-7190

www.memorypharma.com

CONFIDENTIALITY AND NONCOMPETITION AGREEMENT

May 3, 2005

Mr. James R. Sulat

Dear Jim:

This letter is to confirm our understanding with respect to (i) your agreement to protect and
preserve information and property which is confidential and proprietary to Memory Pharmaceuticals
Corp. or its parent, subsidiaries or affiliates, if any, (the “Company”), and (ii) your agreement
not to compete with the Company (the terms and conditions agreed to in this letter shall
hereinafter be referred to as this “Agreement”). In consideration of the mutual promises and
covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby mutually acknowledged, we have agreed as follows:

1. Protected Information. You shall at all times, both during and after the
termination of your employment with the Company, by either you or the Company, with or without
cause, maintain in confidence and shall not, without the prior written consent of the Company,
directly or indirectly use, except in the course of performance of your duties for the Company,
directly or indirectly disclose or give to others any fact, information or document (whether
printed, typed, handwritten, electronic or stored on computer disks, tapes, hard drives or any
other tangible medium) which was disclosed to or developed by you during the course of performing
services for, and/or receiving training from, the Company, and is not generally available to the
public, including but not limited to, information, facts and documents concerning business plans,
research and development, customers, suppliers, licensors, licensees, partners, investors,
affiliates or others, training methods and materials, financial information, sales prospects,
client lists, methodologies, formulae, designs, schematics, charts, Inventions (as defined in
Section 2), or any other scientific, technical, trade or business secret or confidential or
proprietary information (“Confidential Information”) of the Company or of any third party provided
to you during the course of your training and/or employment.

In the event you are questioned by anyone not employed by the Company or by an employee of or
a consultant to the Company not authorized to receive such information, in regard to any
Confidential Information or any other secret or confidential work of the Company, or concerning any
fact or circumstance relating thereto, or in the event that you become aware of the unauthorized
use of Confidential Information by any party, whether competitive with the Company or not, you will
promptly notify the Executive Chairman and Vice President — Legal Affairs of the Company.

 

Exhibit B — Page 1

 

2. Ownership of Ideas, Copyrights and Patents.

(a) Property of the Company. You agree that all ideas, discoveries, creations,
manuscripts and properties, innovations, improvements, know-how, Inventions, designs, developments,
apparatus, techniques, algorithms, software, mask works, methods, and formulae (all of the
foregoing being hereinafter referred to as the “Inventions”) which may be used in the business of
the Company, whether patentable, copyrightable, protectable as mask works or not, which you may
conceive, reduce to practice or develop alone or in conjunction with another, or others, and
whether at the request or upon the suggestion of the Company, or otherwise, during the period in
which you perform services for or at the request of the Company (the “Term”) and, with respect to
Inventions in Field of Interest (as defined below), for a period of one (1) year thereafter, shall
be the sole and exclusive property of the Company, that you shall promptly disclose any such
Inventions to the Company both during and after the Term, and that you shall not publish any such
Inventions without the prior written consent of the Company. You hereby assign to the Company all
of your rights, title and interests in and to all of the foregoing. You further represent and
agree that to the best of your knowledge and belief, none of the Inventions will violate or
infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or
slander against or violate any other rights of any person, firm or corporation, and that you will
use your best efforts to prevent any such violation. You also agree that you will neither disclose
to the Company or any of its employees nor use for their benefit any other person’s or company’s
trade secret or proprietary information, or information which you have agreed not to disclose or
use.

(b) Cooperation. At any time during or after the Term, you agree that you will fully
cooperate with the Company, its attorneys and agents in the preparation and filing of all papers
and other documents as may be required to perfect and protect the Company’s rights in and to any of
such Inventions, including, but not limited to, joining in any proceeding to obtain and enforce
letters patent, copyrights, mask work registrations, trademarks or other legal rights of the United
States and of any and all other countries on such Inventions, provided that the Company will bear
the expense of such proceedings, and that any patent, copyright, mask work registration, trademark
or other legal right so issued to you, personally, shall be assigned by you to the Company without
charge by you.

3. Prohibited Competition.

(a) Certain Acknowledgments and Agreements.

(i) We have discussed, and you recognize and acknowledge the competitive and proprietary
aspects of the business of the Company.

(ii) You further acknowledge and agree that, during the course of your performing services for
the Company, the Company will furnish, disclose or make available to you Confidential Information
related to the Company’s business and that the Company may provide you with unique and specialized
training. You also acknowledge that such Confidential Information and such training have been
developed and will be developed by the Company through the expenditure by the Company of
substantial time, effort and money. You acknowledge that such Confidential Information and
training, if used by you to compete with the Company, will cause irreparable harm to the Company.
You also acknowledge that the Company has a legitimate business interest in protecting its
Confidential Information.

(iii) You acknowledge that the Company is engaged in the research, development or
commercialization of agents to affect memory, cognitive abilities or any related neurological or
psychiatric function (the “Field of Interest”) and that any engagement by you, directly or
indirectly, in the Field of Interest will be deemed competitive. You further acknowledge that the
foregoing

 

Exhibit B — Page 2

 

description is not exclusive and that the Company’s products and services and planned products
and services will change from time to time without notice to you and without formal amendment of
this Agreement.

(b) Covenants Not to Compete. During the Term and for a period of one (1) year
following the expiration or termination of the Term, whether such termination is voluntary or
involuntary, with or without cause, you shall not, without the prior written consent of the
Company:

(i) for yourself or on behalf of any other person or entity, directly or indirectly, either as
principal, agent, employee, consultant, representative or in any other capacity, own, manage,
operate or control, or be connected or employed by, or otherwise associate in any manner with, or
engage in any business which is in the Field of Interest within the United States, Europe or Japan
(the “Restricted Territory”); or

(ii) either individually or on behalf of or through any third party, solicit, divert or
appropriate or attempt to solicit, divert or appropriate, for the purpose or with the effect of
competing with the Company in the Field of Interest or any present or future parent, subsidiary or
other affiliate of the Company which is engaged in a similar business as the Company, any customers
or patrons of the Company, or any prospective customers or patrons with respect to which the
Company has developed or made a sales presentation (or similar offering of services), located
within the Restricted Territory; or

(iii) either individually or on behalf of or through any third party, directly or indirectly,
solicit, entice or persuade or attempt to solicit, entice or persuade any other employees of or
consultants to the Company or any present or future parent, subsidiary or affiliate of the Company,
to leave the services of the Company or any such parent, subsidiary or affiliate for any reason.
You acknowledge that the Company has invested a substantial amount of time and money in attracting
and retaining its employees and in training its employees in the Company’s particular business.
You acknowledge that the Company has a legitimate interest in protecting this investment.

(c) Reasonableness of Restrictions. You further recognize and acknowledge that (i)
the types of activities and employment which are prohibited by Section 3 are narrow and reasonable
in relation to the skills which represent your principal salable asset both to the Company and to
your other prospective employers, and (ii) the geographical scope of the provisions of Section 3 is
reasonable, legitimate and fair to you in light of the geographic scope of the Company’s business,
and in light of the limited restrictions on the type of employment prohibited herein compared to
the types of employment for which you are qualified to earn your livelihood.

4. Survival of Acknowledgments and Agreements. Your acknowledgments and agreements
set forth in Sections 1, 2 and 3 shall survive the expiration or termination of this Agreement and
the termination of your employment with the Company for any reason.

5. Disclosure to Future Employers. You agree that you will provide, and that the
Company may similarly provide in its discretion, a copy of the covenants contained in Sections 1, 2
and 3 of this Agreement to any business or enterprise which you may directly, or indirectly, own,
manage, operate, finance, join, control or in which you participate in the ownership, management,
operation, financing, or control, or with which you may be connected as an officer, director,
employee, partner, principal, agent, representative, consultant or otherwise.

6. Records. Upon termination of your relationship with the Company, you shall deliver
immediately to the Company any property of the Company which may be in your possession including
products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same,

 

Exhibit B — Page 3

 

including, without limitation, any of the foregoing recorded on any computer or any machine
readable medium.

7. No Conflicting Agreements. You have set forth on Exhibit 1 hereto all computer
software and/or Inventions made or conceived by you prior to the date of this Agreement which you
own an interest in and wish to exclude from this Agreement and have listed on Exhibit 1 and
attached copies hereto of any agreements with other parties which may prevent your full compliance
with the terms stated herein. You hereby represent and warrant that, except as set forth on
Exhibit 1, you have no commitments or obligations inconsistent with this Agreement and you hereby
agree to indemnify and hold the Company harmless against loss, damage, liability or expense arising
from any claim based upon circumstances alleged to be inconsistent with such representation and
warranty.

8. General.

(a) Notices. All notices, requests, consents and other communications hereunder shall
be in writing, shall be addressed to the receiving party’s address set forth below or to such other
address as a party may designate by notice hereunder, and shall be either (i) delivered by hand,
(ii) made by telecopy or facsimile transmission, (iii) sent by overnight courier, or (iv) sent by
registered or certified mail, return receipt requested, postage prepaid.

	 	 	 
	If to the Company:

	 	Memory Pharmaceuticals Corp.

100 Philips Parkway

Montvale, New Jersey 07645

Attention: Executive Chairman
	 
	 	 
	With a copy to:

	 	Sills Cummis Epstein & Gross, P.C.

One Riverfront Plaza

Newark, New Jersey 07102

Attention: Ira A. Rosenberg, Esq.
	 
	 	 
	If to Employee:

	 	James R. Sulat
 

All notices, requests, consents and other communications hereunder shall be deemed to have been
given either (i) if by hand, at the time of the delivery thereof to the receiving party at the
address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the
time that receipt thereof has been acknowledged by electronic confirmation or otherwise, (iii) if
sent by overnight courier, on the next business day following the day such notice is delivered to
the courier service, or (iv) if sent by registered or certified mail, on the fifth business day
following the day such mailing is made.

(b) Entire Agreement. This Agreement embodies the entire agreement and understanding
between the parties hereto with respect to the subject matter hereof and supersedes all prior oral
or written agreements and understandings relating to the subject matter hereof. No statement,
representation, warranty, covenant or agreement of any kind not expressly set forth in this
Agreement shall affect, or be used to interpret, change or restrict, the express terms and
provisions of this Agreement.

(c) Modifications and Amendments. The terms and provisions of this Agreement may be
modified or amended only by written agreement executed by the parties hereto.

 

Exhibit B — Page 4

 

(d) Waivers and Consents. The terms and provisions of this Agreement may be waived,
or consent for the departure therefrom granted, only by written document executed by the party
entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to
be or shall constitute a waiver or consent with respect to any other terms or provisions of this
Agreement, whether or not similar. Each such waiver or consent shall be effective only in the
specific instance and for the purpose for which it was given, and shall not constitute a continuing
waiver or consent.

(e) Assignment. The Company may assign its rights and obligations hereunder to any
person or entity who succeeds to all or substantially all of the Company’s business or that aspect
of the Company’s business in which you are principally involved. Your rights and obligations under
this Agreement may not be assigned by you without the prior written consent of the Company.

(f) Benefit. All statements, representations, warranties, covenants and agreements in
this Agreement shall be binding on the parties hereto and shall inure to the benefit of the
respective successors and permitted assigns of each party hereto. Nothing in this Agreement shall
be construed to create any rights or obligations except among the parties hereto, and no person or
entity shall be regarded as a third-party beneficiary of this Agreement.

(g) Governing Law. This Agreement and the rights and obligations of the parties
hereunder shall be construed in accordance with and governed by the law of the State of New Jersey,
without giving effect to the conflict of law principles thereof.

(h) Jurisdiction and Service of Process. Any legal action or proceeding with respect
to this Agreement shall be brought in the courts of the State of New Jersey or of the United States
District Court for the District of New Jersey. By execution and delivery of this Agreement, each
of the parties hereto accepts for itself and in respect of its property, generally and
unconditionally, the jurisdiction of the aforesaid courts. Each of the parties hereto irrevocably
consents to the service of process of any of the aforementioned courts in any such action or
proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its
address set forth in Section 8(a) hereof.

(i) Severability. The parties intend this Agreement to be enforced as written.
However, (i) if any portion or provision of this Agreement shall to any extent be declared illegal
or unenforceable by a duly authorized court having jurisdiction, then the remainder of this
Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion
and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by
law; and (ii) if any provision, or part thereof, is held to be unenforceable because of the
duration of such provision or the geographic area covered thereby, the Company and you agree that
the court making such determination shall have the power to reduce the duration and/or geographic
area of such provision, and/or to delete specific words and phrases (“blue-pencilling”), and in its
reduced or blue-pencilled form such provision shall then be enforceable and shall be enforced.

(j) Interpretation. The parties hereto acknowledge and agree that the terms and
provisions of this Agreement, shall be construed fairly as to all parties hereto and not in favor
of or against a party, regardless of which party was generally responsible for the preparation of
this Agreement.

(k) Headings and Captions. The headings and captions of the various subdivisions of
this Agreement are for convenience of reference only and shall in no way modify, or affect the
meaning or construction of any of the terms or provisions hereof.

 

Exhibit B — Page 5

 

(l) Injunctive Relief. You hereby expressly acknowledge that any breach or threatened
breach of any of the terms and/or conditions set forth in Sections 1, 2 or 3 of this Agreement will
result in substantial, continuing and irreparable injury to the Company. Therefore, you hereby
agree that, in addition to any other remedy that may be available to the Company, the Company shall
be entitled to injunctive or other equitable relief by a court of appropriate jurisdiction, without
posting a bond, in the event of any breach or threatened breach of the terms of Sections 1, 2 or 3
of this Agreement.

(m) No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto
in exercising any right, power or remedy under this Agreement, and no course of dealing between the
parties hereto, shall operate as a waiver of any such right, power or remedy of the party. No
single or partial exercise of any right, power or remedy under this Agreement by a party hereto,
nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall
preclude such party from any other or further exercise thereof or the exercise of any other right,
power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a
waiver of the right of such party to pursue other available remedies. No notice to or demand on a
party not expressly required under this Agreement shall entitle the party receiving such notice or
demand to any other or further notice or demand in similar or other circumstances or constitute a
waiver of the rights of the party giving such notice or demand to any other or further action in
any circumstances without such notice or demand.

(n) Expenses. Should any party breach this Agreement, in addition to all other
remedies available at law or in equity, such breaching party shall pay all of any other party’s
costs and expenses resulting therefrom and/or incurred in enforcing this Agreement, including legal
fees and expenses.

9. Counterparts. This Agreement may be executed in one or more counterparts, and by
different parties hereto on separate counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument.

If the foregoing accurately sets forth our agreement, please so indicate by signing and
returning to us the enclosed copy of this letter.

	 	 	 	 	 
	 	Very truly yours,

MEMORY PHARMACEUTICALS CORP.

 	 
	 	By:  	
 	 
	 	 	Name:  	Tony Scullion 	 
	 	 	Title:  	Chief Executive Officer 	 
	 

Accepted and Approved:

	 	 	 
	 

	 	 
	 	 	 
	James R. Sulat
	 	 

 

Exhibit B — Page 6

 

EXHIBIT 1

PRIOR INVENTIONS AND/OR CONFLICTING AGREEMENTS

 

Exhibit 1 — Page 1Filed by Bowne Pure Compliance

Exhibit 10.2

FOURTH AMENDMENT TO

AMENDED AND RESTATED STRATEGIC ALLIANCE AGREEMENT

(NICOTINIC ALPHA-7 PROGRAM)

This FOURTH AMENDMENT TO AMENDED AND RESTATED STRATEGIC ALLIANCE AGREEMENT (NICOTINIC ALPHA-7
PROGRAM) (this “Amendment”) is effective as of the 15th day of July, 2008, by
and among Memory Pharmaceuticals Corp. (“Memory”), and F. Hoffmann-La Roche Ltd and
Hoffmann-La Roche Inc. (together, “Roche”).

WHEREAS, Memory and Roche have previously entered into an Amended and Restated Strategic
Alliance Agreement (Nicotinic Alpha-7 Program) (including its schedules, exhibits and appendices)
dated as of February 27, 2006, as amended on March 30, 2007, June 18, 2007 and January 14, 2008
(collectively, the “Agreement;” capitalized terms used herein and not otherwise defined
shall have the respective meanings given to them in the Agreement), which sets forth the parties’
rights, duties and obligations under the Agreement; and

WHEREAS, the parties wish to amend the Agreement and agree to the other provisions as set
forth herein.

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the
receipt and sufficiency which are hereby acknowledged, the parties hereby agree that the Agreement
is hereby amended as follows:

	 	1.	 	Clinical Development. Notwithstanding the provisions of Sections 9.1,
7.2(d), Schedule 4 or any other provision of the Agreement to the contrary, the
parties hereby agree that after a Compound achieves [*], Roche (and not Memory) shall
conduct, [*], all Phase 1 clinical trials with respect thereto. In connection
therewith, Roche shall have full decision-making authority; provided that Roche shall
keep Memory informed regarding such activities.

	 	2.	 	Regulatory Filings. Notwithstanding the provisions of Section 9.2 or
any other provision of the Agreement to the contrary, Roche (and not Memory), at
Roche’s sole cost and expense, shall be responsible for the preparation and filing of
any regulatory applications and documents, including, for example, an Investigational
New Drug (IND) application (or foreign equivalent), with respect to each Compound that
has achieved [*]. In connection therewith, Roche shall have full decision-making
authority; provided that Roche shall keep Memory informed regarding such activities.

	 	3.	 	Supply. Notwithstanding the provisions of Section 10.1 or any other
provision of the Agreement to the contrary, (a) Roche (and not Memory), at Roche’s sole
cost and expense, shall be responsible for the manufacture of each Compound [*] with
respect thereto and thereafter, and (b) with regard to Memory Compound designated as
[*], Memory shall transfer ownership to Roche of active pharmaceutical ingredient and
drug product of [*] in the following quantities (and such additional quantities as
Memory determines in its sole discretion, provided

[*] CONFIDENTIAL TREATMENT IS REQUESTED

 

 

 

	 	 	 	that Memory shall use its good faith efforts to transfer ownership to Roche of such
additional quantities thereof that Memory does not intend to use): [*]; provided,
however that Roche shall be responsible (at its sole cost and expense) to arrange
for delivery thereof to Roche from the applicable third party location(s). Except
as specifically provided in the immediately preceding sentence, Memory shall have no
obligation to supply any Compound to Roche.

	 	4.	 	Joint Steering Committee. Notwithstanding the provisions of Section
7.2 or any other provision of the Agreement to the contrary, Memory has the right, but
not the obligation, to participate in the JSC and/or the Working Teams.

	 	5.	 	Certain Additional Activities. From and after conclusion of [*], Roche
(and not Memory), shall be responsible for monitoring the stability programs of the [*]
(including the final reports) described in [*] and [*]. In connection therewith, Roche
shall have full decision-making authority.

	 	6.	 	Diligence. Section 3.1 to the Agreement is hereby amended by deleting
the last two sentences of the first paragraph in their entirety.

	 	7.	 	Event Payments with Respect to Memory Products.

7.1.1. Exhibit C to the Agreement is hereby amended by deleting the below two
payments in their entirety (it being understood and agreed that any payment made by
Roche to Memory prior to the effective date of this Amendment shall not be refunded
to or creditable by Roche):

(a) the $[*] payment due by Roche to Memory upon [*] for any Indication; and

(b) the $[*] payment due by Roche to Memory upon [*] for any Indication.

7.1.2. Exhibit C to the Agreement is hereby amended by adding the following thereto:

	 	 	 
	Event	 	Payment (mio US$)
	[*]
	 	[*]

	 	8.	 	Event Payments with Respect to Collaboration Products. Exhibit D to
the Agreement is hereby amended by deleting the below two payments in their entirety:

(a) the $[*] payment due by Roche to Memory upon [*] for any Indication; and

[*] CONFIDENTIAL TREATMENT IS REQUESTED

 

2

 

(b) the $[*] payment due by Roche to Memory upon [*] for any Indication.

	 	9.	 	Screening Patent Rights. Section 13.3 of the Agreement is hereby
deleted in its entirety. For the avoidance of doubt, it is understood and agreed that
Memory Patent Rights includes, without limitation, the Memory Patent Rights that relate
primarily to Memory’s screening technology for nicotinic alpha-7 agonists or allosteric
modulators which are listed in Exhibit J to the Agreement.

	 	10.	 	No Obligation. For the avoidance of doubt and notwithstanding any
provisions of the Agreement to the contrary, it is understood and agreed that (a)
Memory has no further duties or obligations pursuant to Sections 7.5, 9.1 or 9.2 or
Article 10 of the Agreement or any other obligations pursuant to the Agreement with
respect to research and development, regulatory filings, supply of Compounds or
participation in the JSC and/or Work Teams, and (b) the Strategic Alliance (including,
without limitation, the obligations of the parties to perform activities described in
the Workplan) has expired.

This Amendment, along with the Agreement, shall constitute the entire agreement between the Parties
with respect to the subject matter of the Agreement. All other terms of the Agreement shall remain
in full force and effect. To the extent that there are any inconsistencies between the terms of
the Agreement and the terms of this Amendment, the terms of this Amendment shall prevail in effect.
This Amendment may be executed by facsimile or pdf format and in any number of counterparts, each
of which shall be deemed an original but all of such together shall constitute one and the same
instrument.

[Signature block on the next page]

[*] CONFIDENTIAL TREATMENT IS REQUESTED

 

3

 

IN WITNESS WHEREOF, the parties have executed this Fourth Amendment to be effective as of the
day and year first above written.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	MEMORY PHARMACEUTICALS
CORP.	 	 	 	HOFFMANN-LA ROCHE INC.
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Vaughn M. Kailian
 

Name: Vaughn M. Kailian
	 	 	 	By:
	 	/s/ George W. Johnston
 

Name: George W. Johnston
	 	 	 	 	 	 
	 

	 	Title: President & CEO
	 	 	 	 	 	Title: Vice President	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	F. HOFFMANN-LA ROCHE LTD
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By:
	 	/s/ Christophe Carissimo
 

Name: Christophe Carissimo
	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Title: Global Licensing Director	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By:
	 	/s/ Melanie Frey Wick
 

Name: Dr. Melanie Frey Wick
	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	Title: Authorized Signatory	 	 	 	 	 	 

[*] CONFIDENTIAL TREATMENT IS REQUESTED

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]